Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study

Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy an...

Full description

Bibliographic Details
Main Authors: Daniella Kuzmanovszki, Norbert Kiss, Béla Tóth, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Enikő Kuroli, Eleonóra Imrédi, Tünde Kerner, Mihály Patyánik, Norbert M. Wikonkál, Ákos Szabó, Valentin Brodszky, Fanni Rencz, Péter Holló
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Journal of Clinical Medicine
Subjects:
cemiplimab
cutaneous squamous cell carcinoma
PD-1 inhibitor
immune checkpoint inhibitor
adverse event
immunotherapy
Online Access:https://www.mdpi.com/2077-0383/12/18/5966

Similar Items

Similar Items